Oct 9
|
Veru Inc (VERU) Q3 2024 Earnings Call Highlights: Strategic Cost Management and Revenue Growth ...
|
Aug 8
|
Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates
|
Aug 8
|
Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results
|
Jul 29
|
Veru to Participate in the BTIG Virtual Biotechnology Conference
|
Jun 24
|
Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions
|
Jun 18
|
Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024
|
Jun 17
|
Veru Reminds Shareholders to Vote in Advance of Tomorrow’s Deadline for 2024 Annual Meeting of Shareholders
|
Jun 10
|
Veru to Present at the American Diabetes Association's 84th Scientific Sessions
|
May 15
|
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
|
May 14
|
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week
|
May 9
|
Veru Inc (VERU) Q2 2024 Earnings Call Transcript Highlights: Strategic Focus and Financial Recovery
|
May 8
|
Veru Inc. (VERU) Fiscal 2024 Q2 Earnings: Clinical Advances Amid Financial Strains
|
May 8
|
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
|
May 2
|
Veru to Present at the GLP-1 Based Therapeutics Summit
|
May 1
|
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
|
Apr 30
|
Veru Inc. (VERU) Just Flashed Golden Cross Signal: Do You Buy?
|
Apr 30
|
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
|
Apr 25
|
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
|
Apr 17
|
What Makes Veru (VERU) a New Buy Stock
|
Apr 1
|
Veru Announces Date of 2024 Annual Meeting of Shareholders
|